Come and hear Shaun Day from Greatland Gold #GGP, Cathal Friel and Jeremy Skillington from Poolbeg Pharma #POLB, George Bennett from Rainbow Rare Earths #RBW and Helium One CEO David Minchin #HE1 present tomorrow evening. Register here.

Less Ads, More Data, More Tools Register for FREE

Shire slumps after Credit Suisse cuts price target, earnings forecast

Mon, 26th Oct 2015 10:23

(ShareCast News) - Shire Pharmaceuticals declined on Monday after Credit Suisse cut its price target and forecasts for 2016 earnings.

Analysts at the Swiss broker said while Shire has leading positions in pricing power and top line growth, there are "multiple overhangs" including the proposed Baxalta acquisition, the hold-up in receiving regulatory approval of lifitegrast and Lialda patent challenges.

"We are cutting our price target from £56.80 to £54 to reflect market moves and a 3% cut in 2016 earnings per share," Credit Suisse said, issuing a 'neutral' rating for the stock.

Shire, which reported growth in third quarter sales and profit last week, said it is continuing to pursue its bid for US company Baxalta but did not indicate whether it was sweetening its offer. A bid for the firm was made public in August.

"The Baxalta hostile bid remains the single biggest unknown at Shire. Fundamentally we believe it is an attractive combination with significant revenue and cost synergies," said Credit Suisse.

Meanwhile the US Food and Drug Administration has asked for more information about lifitegrast, a medicine for dry eye disease, before approving the drug.

In another hurdle for Shire, the US Patent and Trademark Office is taking a second look at a patent that protects the company's colitis medicine Lialda from generic competition.

Shares in Shire were down 0.71% to 4,608p at 1100 GMT.

Related Shares

More News

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

6 Sep 19 07:54

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

14 Aug 19 06:45

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

17 Jul 19 17:55

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

16 May 19 18:35

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.